PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDasatinib
Sprycel(dasatinib)
Dasatinib, Phyrago, Sprycel (dasatinib) is a small molecule pharmaceutical. Dasatinib was first approved as Sprycel on 2006-06-28. It is used to treat lymphoid leukemia and myeloid leukemia in the USA. It has been approved in Europe to treat BCR-ABL positive chronic myelogenous leukemia and precursor cell lymphoblastic leukemia-lymphoma. The pharmaceutical is active against tyrosine-protein kinase ABL1. In addition, it is known to target putative serine/threonine-protein kinase SIK1B, proto-oncogene tyrosine-protein kinase Src, serine/threonine-protein kinase SIK2, and serine/threonine-protein kinase SIK3.
Download report
Favorite
Drugs Approved for Childhood Cancers
BMS
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Dasatinib, Sprycel
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dasatinib
Tradename
Company
Number
Date
Products
SPRYCELBristol Myers SquibbN-021986 RX2006-06-28
6 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
dasatinibNew Drug Application2024-09-04
phyragoNew Drug Application2024-07-29
sprycelNew Drug Application2024-07-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
myeloid leukemia—D007951C92
lymphoid leukemia—D007945C91
Agency Specific
FDA
EMA
Expiration
Code
DASATINIB, SPRYCEL, BRISTOL MYERS SQUIBB
2026-06-21PED
2025-12-21ODE-225
2025-05-09PED
2024-11-09ODE-164
Patent Expiration
Patent
Expires
Flag
FDA Information
Dasatinib, Sprycel, Bristol Myers Squibb
74917252026-03-28DS, DP
86801032025-02-04DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EA: Bcr-abl tyrosine kinase inhibitors
— L01EA02: Dasatinib
HCPCS
No data
Clinical
Clinical Trials
389 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C955510221834198
Myeloid leukemiaD007951—C92386510625132
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—316311730131
Lymphoid leukemiaD007945—C91274381676
Precursor cell lymphoblastic leukemia-lymphomaD054198——2537111671
Myeloid leukemia chronic-phaseD015466——72533946
Multiple myelomaD009101—C90.075—1—13
Plasma cell neoplasmsD054219——54—1—10
Hematologic neoplasmsD019337——43—1—7
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Philadelphia chromosomeD010677——16235—341
LymphomaD008223—C85.910141—121
Myeloid leukemia acuteD015470—C92.01091—319
Prostatic neoplasmsD011471—C614131——16
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A121—37
Myeloid leukemia accelerated phaseD015465——311——5
Residual neoplasmD018365——131——4
Central nervous system neoplasmsD016543——221——3
Hematopoietic stem cell transplantationD018380———11——1
B-cell leukemiaD015448———11——1
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C802214——236
RecurrenceD012008——1111——223
Breast neoplasmsD001943EFO_0003869C50820———22
CarcinomaD002277—C80.0610——117
Lung neoplasmsD008175HP_0100526C34.90511———14
Non-small-cell lung carcinomaD002289——69———13
Blast crisisD001752——85———12
B-cell chronic lymphocytic leukemiaD015451—C91.158———11
Pancreatic neoplasmsD010190EFO_0003860C2546———10
Non-hodgkin lymphomaD008228—C85.975———10
Show 128 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hodgkin diseaseD006689—C814————4
Mucinous adenocarcinomaD002288——2————2
Waldenstrom macroglobulinemiaD008258HP_0005508C88.02————2
MycosesD009181—B35-B492————2
Mycosis fungoidesD009182—C84.02————2
Drug interactionsD004347——2————2
Myeloproliferative disordersD009196—D47.11————1
AnemiaD000740HP_0001903D64.91————1
Leukemia myeloid chronic atypical bcr-abl negativeD054438—C92.21————1
Myelodysplastic-myeloproliferative diseasesD054437——1————1
Show 32 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437HP_0000083N19————11
Pleural effusionD010996HP_0002202J90————11
FatigueD005221HP_0012378R53.83————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDasatinib
INNdasatinib
Description
Dasatinib (anhydrous) is an aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN). It has a role as a tyrosine kinase inhibitor, an anticoronaviral agent and an antineoplastic agent. It is a secondary amino compound, a tertiary amino compound, an organochlorine compound, an aminopyrimidine, a member of 1,3-thiazoles, a monocarboxylic acid amide, a N-arylpiperazine and a N-(2-hydroxyethyl)piperazine. It is a conjugate base of a dasatinib(1+).
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Identifiers
PDB—
CAS-ID302962-49-8
RxCUI1546019
ChEMBL IDCHEMBL1421
ChEBI ID49375
PubChem CID3062316
DrugBankDB01254
UNII IDX78UG0A0RN (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SRC
SRC
LOC102724428
LOC102724428
Organism
Homo sapiens
Gene name
SRC
Gene synonyms
SRC1
NCBI Gene ID
6714
Protein name
proto-oncogene tyrosine-protein kinase Src
Protein synonyms
p60-Src, pp60c-src, Proto-oncogene c-Src, protooncogene SRC, Rous sarcoma, tyrosine kinase pp60c-src, tyrosine-protein kinase SRC-1, v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog
Uniprot ID
Q9H5A8
Mouse ortholog
Src (20779)
proto-oncogene tyrosine-protein kinase Src (Q2M4I4)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Sprycel – Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 22,717 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
33,380 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use